He, Min-Ke
Zou, Ru-Hai
Li, Qi-Jiong
Zhou, Zhong-Guo
Shen, Jing-Xian
Zhang, Yong-Fa
Yu, Zi-Shan
Xu, Li
Shi, Ming http://orcid.org/0000-0002-4051-4474
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis
https://doi.org/10.1007/s00270-017-1874-z
Funding for this research was provided by:
National Key R&D Program of China (2017YFA0505803)
National Natural Science Foundation of China (No. 81625017, No. 81572385)
Fundamental Research Funds for the Central Universities of China (No. 16ykjc36)
Article History
Received: 29 September 2017
Accepted: 29 December 2017
First Online: 11 January 2018
Compliance with Ethical Standards
:
: The authors declare that they have no conflict of interest. The manuscript has not been submitted to more than one journal for simultaneous consideration. The manuscript has not been published previously (partly or in full). A single study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time. No data have been fabricated or manipulated (including images) to support your conclusions. No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities—tacitly or explicitly—at the institute/organization where the work has been carried out, before the work is submitted.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written informed consent. The study was approved by the institutional review board.